• Launched three new products in Q3 and Q4
• Completed acquisition of Flanders Scientific in April
• Anticipated FY26 sales of ~$40m, with H2'FY26 at ~$16m
• Expected FY26 EBITDA between $2.5m - $3.5m
• Improved contribution margins expected to continue

Atomos Limited (ASX:AMS) reported a mixed trading update for FY26, highlighting several operational milestones including the launch of three new products and the acquisition of Flanders Scientific. Despite these achievements, the company anticipates FY26 sales to be around $40 million, with H2'FY26 sales expected to be approximately $16 million, lower than previous guidance of $23.7 million. The company also expects FY26 EBITDA to be in the range of $2.5 million to $3.5 million. The shortfall in sales is attributed to timing and demand factors, including delayed shipments and softer end consumer demand.

FY26 sales expected ~$40m, H2'FY26 ~$16m; FY26 EBITDA $2.5m - $3.5m

Atomos expects improved contribution margins to continue in future periods.